Jnana Therapeutics specializes in discovering and developing medicines to expand the universe of therapeutic impact. By combining deep drug discovery, development expertise and their proprietary technology, Jnana is unlocking highly validated but previously undruggable targets. Drug discovery involves use of Jnana’s chemoproteomic platform, Reactive Affinity Probe Interaction Discovery (RAPID), a proprietary ligand platform to identify small molecule binders irrespective of the target. The unbiased approach of RAPID allows challenging targets, such as transcription factors and helicases, to be investigated. By using their RAPID platform, Jnana is developing a pipeline targeting many rare genetic diseases, immune-mediated diseases and oncology.